Tashkin D P, Trevor E, Chopra S K, Taplin G V
Am J Med. 1980 Jan;68(1):14-26. doi: 10.1016/0002-9343(80)90156-4.
In 12 asthmatic subjects with mild to severe airways obstruction, we compared the relative magnitude and sites of airway dilatation of a beta-adrenergic stimulant administered by different routes. Specific airway conductance (SGaw), peak expiratory flow, the sum of the absolute volume of isoflow and residual volume as a percentage of total lung capacity (capacity of isoflow) and the ratio of maximal expiratory flow at 50 per cent of vital capacity breathing 80 per cent helium-20 per cent oxygen to that breathing air (ratio Vmax50) were determined before and after the administration of aerosolized terbutaline (0.5 mg), subcutaneous terbutaline (0.5 mg) or placebo. Increases in SGaw and peak expiratory flow of greater than or equal to 25 per cent were considered to indicate significant dilatation of central airways; increases in ratio Vmax50 of greater than or equal to 0.10 and decreases in capacity of isoflow of greater than or equal to 10 per cent were assumed to reflect dilatation of peripheral airways. In addition, radioaerosol and radioxenon lung imaging was performed to determine the relationship between changes in lung imaging patterns and changes in physiologic indices in response to bronchodilator therapy. Placebo caused little change in lung function or lung imaging. After inhaled terbutaline, SGaw and peak expiratory flow increased greater than or equal to 25 per cent in seven subjects, ratio Vmax50 increased greater than or equal to 0.10 in only three subjects, capacity of isoflow decreased greater than or equal to 10 per cent in only one subject, radioaerosol images showed less central deposition in nine subjects and radioxenon images showed improved distribution and/or washout of xenon in five subjects. After the administration of subcutaneous terbutaline, SGaw and peak expiratory flow increased greater than or equal to 25 per cent in 10 subjects, ratio Vmax50 increased greater than or equal to 0.10 in 10 subjects, capacity of isoflow decreased greater than or equal to 10 per cent in 11 subjects, and radioaerosol and xenon images showed improvement in 11 and eight subjects, respectively. These findings are consistent with the action of inhaled terbutaline mainly on large airways and of subcutaneous terbutaline on both large and small airways. Although reduced central radioaerosol deposition correlated well with physiologic evidence of large airway dilatation, improvement in xenon distribution and washout could be attributed to dilatation of either large and/or small airways.
在12名患有轻至重度气道阻塞的哮喘患者中,我们比较了通过不同途径给予的β-肾上腺素能兴奋剂气道扩张的相对程度和部位。在雾化吸入特布他林(0.5毫克)、皮下注射特布他林(0.5毫克)或安慰剂前后,测定了比气道传导率(SGaw)、呼气峰流量、等流量绝对容积与残气量之和占肺总量的百分比(等流量容量)以及在肺活量的50%时呼吸80%氦-20%氧时的最大呼气流量与呼吸空气时的最大呼气流量之比(Vmax50比值)。SGaw和呼气峰流量增加大于或等于25%被认为提示中央气道有显著扩张;Vmax50比值增加大于或等于0.10以及等流量容量减少大于或等于10%被假定反映外周气道扩张。此外,进行放射性气溶胶和放射性氙肺显像以确定肺显像模式的变化与支气管扩张剂治疗后生理指标变化之间的关系。安慰剂对肺功能或肺显像几乎没有影响。吸入特布他林后,7名患者的SGaw和呼气峰流量增加大于或等于25%,仅3名患者的Vmax50比值增加大于或等于0.10,仅1名患者的等流量容量减少大于或等于10%,放射性气溶胶显像显示9名患者中央沉积减少,放射性氙显像显示5名患者氙的分布和/或洗脱改善。皮下注射特布他林后,10名患者的SGaw和呼气峰流量增加大于或等于25%,10名患者的Vmax50比值增加大于或等于0.10,11名患者的等流量容量减少大于或等于10%,放射性气溶胶和氙显像分别显示11名和8名患者有改善。这些发现与吸入特布他林主要作用于大气道以及皮下注射特布他林作用于大气道和小气道的作用一致。虽然中央放射性气溶胶沉积减少与大气道扩张的生理证据密切相关,但氙分布和洗脱的改善可能归因于大气道和/或小气道的扩张。